Takeda partners with Noile-Immune on next-gen CAR-T pipeline for solid tumors – Endpoints News
Endpoints News |
Takeda partners with Noile-Immune on next-gen CAR–T pipeline for solid tumors
Endpoints News But these first therapies, which use reengineered T cells extracted from patients to attack hematological malignancies, have been limited in scope. Takeda and Tokyo-based Noile-Immune hope to use new tech developed with researchers at Yamaguchi … |
